GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infinity Pharmaceuticals Inc (OTCPK:INFIQ) » Definitions » EPS without NRI
中文

Infinity Pharmaceuticals (Infinity Pharmaceuticals) EPS without NRI

: $-0.47 (TTM As of Jun. 2023)
View and export this data going back to 2000. Start your Free Trial

Infinity Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Jun. 2023 was $-0.11. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.47.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 15.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Infinity Pharmaceuticals's EPS without NRI or its related term are showing as below:

INFIQ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -137.8   Med: 6.3   Max: 64
Current: 15.8

During the past 13 years, Infinity Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 64.00% per year. The lowest was -137.80% per year. And the median was 6.30% per year.

INFIQ's 3-Year EPS without NRI Growth Rate is ranked better than
63.5% of 1296 companies
in the Biotechnology industry
Industry Median: 4.45 vs INFIQ: 15.80

Infinity Pharmaceuticals's EPS (Diluted) for the three months ended in Jun. 2023 was $-0.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.46.

Infinity Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2023 was $-0.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.46.


Infinity Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Infinity Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 -0.85 -0.69 -0.53 -0.51

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -0.12 -0.11 -0.13 -0.11

Competitive Comparison

For the Biotechnology subindustry, Infinity Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infinity Pharmaceuticals PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's PE Ratio without NRI falls into.



Infinity Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infinity Pharmaceuticals  (OTCPK:INFIQ) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Infinity Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Infinity Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Infinity Pharmaceuticals (Infinity Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
Executives
Adelene Q Perkins director, officer: President & CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Stephane Peluso officer: Chief Scientific Officer 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Robert Jr. Ilaria officer: Chief Medical Officer 1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Samuel Agresta officer: Chief Medical Officer 784 MEMORIAL DR., CAMBRIDGE MA 02139
David W Beier director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lawrence E Bloch officer: EVP, CFO & CBO
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael C Venuti director

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Headlines

From GuruFocus